Moscow, November 24 The official website of Russia’s “satellite-V” vaccine released information on the 24th that the second mid-term analysis of the third phase of the “satellite-V” vaccine clinical data shows that the effectiveness of the vaccine exceeds 95%.
According to the source, 18,794 volunteers who were vaccinated and placebos were counted, and by the 23rd, there were 39 people infected with the novel coronavirus. Based on this statistics, it is concluded that on the 28th day of the first vaccination (the 7th day of the second vaccination), the vaccine effectiveness can reach 91.4%, the 42nd day of the first vaccination (the 21st day of the second injection), and the vaccine effectiveness of the vaccine is more than 95%.
According to the source, 40,000 volunteers participated in the randomized, double-blind and controlled trial of the third phase of the “Satellite-V” vaccine. At present, 22,000 people have been vaccinated once, and more than 19,000 people have been vaccinated twice. The study found no unintended adverse reactions.
Russian Deputy Prime Minister Golikova said on the same day that 117,000 “satellite-V” vaccines have entered circulation, and more than 2 million vaccines are planned to be produced by the end of this year. First of all, high-risk groups, medical workers and teachers will be vaccinated. The large-scale vaccination of residents will begin in 2021.
Golikova said that the vaccine developed by the Ochumakov Federal Center for Immunization and Biological Products Research and Development will conclude clinical trials at the end of December this year.
Russia’s Direct Investment Fund (Vaccine Cooperative Producer) announced on the 24th that Russia will provide the first batch of vaccines to international customers in January 2021. International customers who have recently submitted procurement applications can obtain supplies in March 2021.
The “Satellite-V” vaccine, developed by the National Research Center for Epidemiology and Microbiology of Ogamarea, is a human adenovirus vector vaccine, which was registered in Russia on August 11. Previously, the results of the analysis of the clinical three-phase analysis of the “satellite-V” vaccine showed that the vaccine can be effective up to 92%.